BACKGROUND: Despite increased utilization of contralateral prophylactic mastectomy (CPM), there is insufficient evidence that it improves survival in average-risk women with unilateral breast cancer. CPM may be of heightened interest to patients with triple negative breast cancer (TNBC) because these patients are more likely to have BRCA1 mutation-associated disease and are not candidates for the chemoprevention benefits of adjuvant endocrine therapy. METHODS: Survival and recurrence outcomes were evaluated for all TNBC patients from a multi-institutional database (1999-2018) at two academic cancer programs in two metropolitan cities of the Northeast and Midwest. Median follow-up time was 3.7 years. RESULTS: Seven hundred and nighty six TNBC patients were evaluated and 15.45% underwent CPM. Women undergoing CPM were more likely to be white (p < 0.001), younger (p < 0.001), and underwent genetic testing (p < 0.001). A borderline survival benefit was observed for TNBC patients undergoing CPM (5-year overall survival 95.1% vs. 85.0%; p = 0.05). There was no difference in survival when BRCA mutation carriers were excluded (5-year overall survival 94.1% vs. 85.2%; p = 0.12). For BRCA mutation carriers, a numeric trend was observed for improved survival for patients undergoing CPM (5-year overall survival 97.2% vs. 84.1%; p = 0.35). Among patients not undergoing CPM, the rate of developing a new primary breast cancer was 2.2% (15/673). Among these 15 patients, 20% (3/15) were known BRCA mutation carriers. CONCLUSIONS: Our data demonstrate no survival benefit for TNBC patients without BRCA1/2 mutations undergoing CPM.
References
Nash R, Goodman M, Lin CC, et al. State variation in the receipt of a contralateral prophylactic mastectomy among women who received a diagnosis of invasive unilateral early-stage breast cancer in the United States, 2004–2012. JAMA Surg. 2017;152:648–57.
[DOI: 10.1001/jamasurg.2017.0115]
Wang T, Baskin AS, Dossett LA. Deimplementation of the choosing wisely recommendations for low-value breast cancer surgery: a systematic review. JAMA Surg. 2020;558:759–70.
[DOI: 10.1001/jamasurg.2020.0322]
Pesce C, Liederbach E, Wang C, et al. Contralateral prophylactic mastectomy provides no survival benefit in young women with estrogen receptor-negative breast cancer. Ann Surg Oncol. 2014;21:3231–9.
[DOI: 10.1245/s10434-014-3956-3]
Kurian AW, Lichtensztajn DY, Keegan TH, et al. Use of and mortality after bilateral mastectomy compared with other surgical treatments for breast cancer in California, 1998–2011. JAMA. 2014;312:902–14.
[DOI: 10.1001/jama.2014.10707]
Nichols HB, Berrington de González A, Lacey JV Jr, et al. Declining incidence of contralateral breast cancer in the United States from 1975 to 2006. J Clin Oncol. 2011;29:1564–9.
[DOI: 10.1200/JCO.2010.32.7395]
Broët P, de la Rochefordière A, Scholl SM, et al. Contralateral breast cancer: annual incidence and risk parameters. J Clin Oncol. 1995;13:1578–83.
[DOI: 10.1200/JCO.1995.13.7.1578]
Boughey JC, Attai DJ, Chen SL, et al. Contralateral prophylactic mastectomy consensus statement from the American Society of Breast Surgeons: additional considerations and a framework for shared decision making. Ann Surg Oncol. 2016;23:3106–11.
[DOI: 10.1245/s10434-016-5408-8]
Newman LA. Contralateral prophylactic mastectomy: is it a reasonable option? JAMA. 2014;312:895–7.
[DOI: 10.1001/jama.2014.11308]
Foulkes WD, Stefansson IM, Chappuis PO, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst. 2003;95:1482–5.
[DOI: 10.1093/jnci/djg050]
Schroeder MC, Tien YY, Erdahl LM, et al. The relationship between contralateral prophylactic mastectomy and breast reconstruction, complications, breast-related procedures, and costs: a population-based study of health insurance data. Surgery. 2020;168:859–67.
[DOI: 10.1016/j.surg.2020.06.030]
Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31:3997–4013.
[DOI: 10.1200/JCO.2013.50.9984]
Baskin AS, Wang T, Bredbeck BC, et al. Trends in contralateral prophylactic mastectomy utilization for small unilateral breast cancer. J Surg Res. 2021;262:71–84.
[DOI: 10.1016/j.jss.2020.12.057]
Findlay-Shirras L, Lima I, Smith G, et al. Canada follows the US in the rise of bilateral mastectomies for unilateral breast cancer: a 23-year population cohort study. Breast Cancer Res Treat. 2021;185:517–25.
[DOI: 10.1007/s10549-020-05965-z]
Chung A, Huynh K, Lawrence C, et al. Comparison of patient characteristics and outcomes of contralateral prophylactic mastectomy and unilateral total mastectomy in breast cancer patients. Ann Surg Oncol. 2012;19:2600–6.
[DOI: 10.1245/s10434-012-2299-1]
Zeichner SB, Zeichner SB, Ruiz AL, et al. Improved long-term survival with contralateral prophylactic mastectomy among young women. Asian Pac J Cancer Prev. 2014;15:1155–62.
[DOI: 10.7314/APJCP.2014.15.3.1155]
Bedrosian I, Hu CY, Chang GJ. Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients. J Natl Cancer Inst. 2010;102:401–9.
[DOI: 10.1093/jnci/djq018]
Robinson E, Rennert G, Rennert HS, Neugut AI. Survival of first and second primary breast cancer. Cancer. 1993;71:172–6.
[DOI: 10.1002/1097-0142(19930101)71]
Gajalakshmi CK, Shanta V, Hakama M. Survival from contralateral breast cancer. Breast Cancer Res Treat. 1999;58:115–22.
[DOI: 10.1023/A]
Newman LA. Decision making in the surgical management of breast cancer-part 1: LUMPECTOMY, MASTECTOMY, and contralateral prophylactic mastectomy. Oncology. 2017;31:359–68.
[PMID: 28512732]
van Sprundel TC, Schmidt MK, Rookus MA, et al. Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br J Cancer. 2005;93:287–92.
[DOI: 10.1038/sj.bjc.6602703]
Metcalfe K, Gershman S, Ghadirian P, et al. Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ. 2014;348:g226.
[DOI: 10.1136/bmj.g226]
Li X, You R, Wang X, et al. Effectiveness of prophylactic surgeries in BRCA1 or BRCA2 mutation carriers: a meta-analysis and systematic review. Clin Cancer Res. 2016;22:3971–81.
[DOI: 10.1158/1078-0432.CCR-15-1465]
Metcalf KA, Eisen A, Poll A, et al. Frequency of contralateral prophylactic mastectomy in breast cancer patients with negative BRCA1 and BRCA2 rapid genetic test result. Ann Surg Oncol. 2021;28:4967–73.
[DOI: 10.1245/s10434-021-09855-6]
Guo F, Scholl M, Fuchs EL, et al. BRCA testing and testing results among women 18–65 years old. Prev Med Rep. 2022;26:101738.
[DOI: 10.1016/j.pmedr.2022.101738]
Clark S, Bluman LG, Borstelmann N, et al. Patient motivation, satisfaction, and coping in genetic counseling and testing for BRCA1 and BRCA2. J Genet Couns. 2000;9:219–35.
[DOI: 10.1023/A]
Brown M, Bauer K, Pare M. Tumor marker phenotype concordance in second primary breast cancer, California, 1999–2004. Breast Cancer Res Treat. 2010;120:217–27.
[DOI: 10.1007/s10549-009-0469-z]
Rosenberg SM, Greaney ML, Patenaude AF, et al. “I don’t want to take chances”: a qualitative exploration of surgical decision making in young breast cancer survivors. Psychooncology. 2018;27:1524–9.
[DOI: 10.1002/pon.4683]
Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429–34.
[DOI: 10.1158/1078-0432.CCR-06-3045]
Association for Molecular Pathology et al. Myriad Genetics, Inc. et al. 133 S. Ct. 2107 June 13, 2013
